Clicky

Arcellx, Inc.(ACLX)

Description: Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Its lead ddCAR product candidate is CART-ddBCMA, which is in Phase 1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The company is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Organ Systems Solid Tumors Immunotherapies Acute Myeloid Leukemia Multiple Myeloma Protein Kinase Inhibitor Myelodysplastic Syndrome Antibody Drug Conjugate Incurable Diseases Devimistat

Home Page: arcellx.com

ACLX Technical Analysis

25 West Watkins Mill Road
Gaithersburg, MD 20878
United States
Phone: 240 327 0603


Officers

Name Title
Mr. Rami Elghandour Chairman, CEO & Pres
Mr. Neeraj P. Teotia Chief Commercial Officer
Dr. Christopher R. Heery M.D. Chief Medical Officer
Ms. Michelle Lim Gilson Chief Financial Officer
Mr. Michael Dombeck M.B.A. Chief Operating Officer
Mr. Narinderjeet Singh M.S. Chief Technical Officer
Mr. David Tice Ph.D. Chief Scientific Officer
Ms. Myesha Lacy VP of Investor Relations
Ms. Maryam Abdul-Kareem J.D., M.S. Gen. Counsel
Ms. Kate Aiken Chief People Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 6.1247
Price-to-Sales TTM: 0
IPO Date: 2022-02-04
Fiscal Year End: December
Full Time Employees: 78
Back to stocks